引用本文:贾祖强.老年慢性阻塞性肺病加重期应用噻托溴铵普米克令舒及万托林的效果及安全性[J].中国临床新医学,2017,10(1):64-66.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1630次   下载 1372 本文二维码信息
码上扫一扫!
分享到: 微信 更多
老年慢性阻塞性肺病加重期应用噻托溴铵普米克令舒及万托林的效果及安全性
贾祖强
457000 河南,濮阳市红十字医院内科
摘要:
[摘要] 目的 探讨噻托溴铵、普米克令舒及万托林在老年慢性阻塞性肺病加重期临床治疗效果及安全性。方法 选取2014-12~2015-12该院诊治的80例老年慢性阻塞性肺部加重期患者,根据随机数字表法将患者分为对照组和治疗组两组,每组40例。对照组采用普米克令舒及万托林治疗,治疗组在对照组基础上联合噻托溴铵治疗,治疗10 d,比较两组临床疗效。结果 治疗组治疗后喘憋、退热、咳嗽、干湿啰音消失时间以及住院时间显著短于对照组(P<0.05);治疗组药物不良反应发生率为7.5%,显著低于对照组的17.5%(P<0.05)。结论 老年慢性阻塞性肺部加重期患者用普米克令舒及万托林治疗基础上联合噻托溴铵治疗效果较好,值得推广应用。
关键词:  噻托溴铵  普米克令舒  万托林  老年慢性阻塞性肺病  疗效  安全性
DOI:10.3969/j.issn.1674-3806.2017.01.20
分类号:R 56
基金项目:
Effect and safety studies of tiotropium, Pulmicort and Ventolin on elderly patients with acute exacerbation of chronic obstructive pulmonary disease
JIA Zu-qiang
Department of Internal Medicine, Red Cross Hospital of Puyang City, Henan 457000, China
Abstract:
[Abstract] Objective To investigate the clinical effect and safety of tiotropium, Pulmicort and Ventolin on elderly patients with acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods Eighty elderly patients with acute exacerbation from December 2014 to December 2015 were randomly divided into two groups according to the different treatment methods, with 40 cases in each group. The control group was treated with Pulmicort and Ventolin.The experimental group was treated with tiotropium on basis of the therapy in the control group.Results The disappearance time of wheezing, fever, cough, dry and wet lung rales and the length of hospital stay in the experimental group were significantly shorter than those in the control group after the treatment(P<0.05); The incidence of adverse reactions(7.5%) was significantly lower than that in the control group(17.5%)(P<0.05).Conclusion The combination treatment of Pulmicort ,Ventolin and tiotropium is safe and effective in the treatment of acute exacerbation of COPD.
Key words:  Tiotropium  Pulmicort  Ventolin  Elderly patients with chronic obstructive pulmonary disease  Treatment  Safety